Cisplatin combined with laser‑activated nanotherapy as an adjuvant therapy for head and neck cancer

Lee,Gee   Young; Myers,Jonté  A.; Perez,Sandra  M.; Singh,Karan  P.; Green,Hadiyah  N.

doi:10.3892/ijo.2020.5126

Cisplatin combined with laser‑activated nanotherapy as an adjuvant therapy for head and neck cancer

Authors:
- Gee Young Lee
- Jonté A. Myers
- Sandra M. Perez
- Karan P. Singh
- Hadiyah N. Green
View Affiliations

Affiliations: Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA, Department of Learning Sciences, College of Education and Human Development, Georgia State University, Atlanta, GA 30303, USA, Department of Epidemiology and Biostatistics, School of Community and Rural Health, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
Published online on: September 22, 2020 https://doi.org/10.3892/ijo.2020.5126
Pages: 1169-1178

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck cancers (HNCs), in general, have a poor prognosis with a worldwide 5‑year survival rate of <50%. Numerous HNC patients with locoregionally advanced, difficult‑to‑treat, inoperable, recurrent and drug‑resistant tumors may require additional treatment options when the standard of care surgery, chemotherapy and radiation are not viable. The poor outcomes justify exploring strategies to increase the efficacy of lower doses of drugs, such as cisplatin, by combining these drugs with other treatment modalities and manipulating the dosing schedule. Cisplatin is a standard and effective anticancer drug; however, some patients cannot tolerate the side‑effects or exhibit drug resistance. Adjuvant therapies may lower the effective dose, decrease side‑effects, address drug resistance and improve overall survival outcomes, particularly for patients with difficult‑to‑treat tumors. The present study focuses on combining cisplatin with laser‑activated nanotherapy (LANT), as an adjuvant HNC therapy, with the aim of enhancing the therapeutic efficacy of lower doses of cisplatin and decreasing treatment times. The results demonstrate the potential of cisplatin and LANT co‑therapy as a possible addition to the adjuvant therapy options for HNC using 3 cell lines: Detroit 562, FaDu and CAL 27 cells. Combining cisplatin with LANT demonstrated up to a 5.4‑fold greater therapeutic efficacy than with cisplatin monotreatment. The most effective combination in the present study was 1 µM Cis + 5 nM LANT, which demonstrated cell death comparable to 5.9, 4.2 and 5.3 µM of Cis monotreatment, in Detroit 562, FaDu and CAL 27 cells, respectively. This result suggests that a lower cisplatin dose may be combined with LANT to achieve the same therapeutic efficacy as that obtained with higher doses of cisplatin monotreatment. The combination of LANT and cisplatin suggests that LANT may enhance the therapeutic efficiency of low doses of cisplatin, decrease treatment times and improve patient outcomes.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J and Pignon JP; MACH-CH Collaborative group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol. 100:33–40. 2011. View Article : Google Scholar : PubMed/NCBI
4	Marur S and Forastiere AA: Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 91:386–396. 2016. View Article : Google Scholar : PubMed/NCBI
5	Dauzier E, Lacas B, Blanchard P, Le QT, Simon C, Wolf G, Janot F, Horiuchi M, Tobias JS, Moon J, et al: Role of chemo-therapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncol. 95:106–114. 2019. View Article : Google Scholar : PubMed/NCBI
6	Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis. 10:5402019. View Article : Google Scholar : PubMed/NCBI
7	Pendleton KP and Grandis JR: Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck. Clin Med Insights Ther. 2013: View Article : Google Scholar : 2013.PubMed/NCBI
8	Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
9	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
10	Furqan M, Snyders TP, Saqlain MU, Mott SL, Laux D, Snow A, Anderson CM, Watkins JM and Clamon GH: Comparing high-dose cisplatin with cisplatin-based combination chemo-therapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer Med. 8:2730–2739. 2019. View Article : Google Scholar : PubMed/NCBI
11	Florea AM and Büsselberg D: Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 3:1351–1371. 2011. View Article : Google Scholar
12	Towne TG and Murray A: Encyclopedia of Toxicology. 3rd edition. Academic Press; 2014
13	Pratt WB and Ruddon RW: The anticancer drugs. Oxford University Press; 1979
14	Makovec T: Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 53:148–158. 2019. View Article : Google Scholar : PubMed/NCBI
15	Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A, Koike H, Kouzu Y, Shinozuka K, Nakatani K, Negoro K, et al: Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010. View Article : Google Scholar
16	Marur S and Forastiere AA: Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 83:489–501. 2008. View Article : Google Scholar : PubMed/NCBI
17	American Cancer Society: Global cancer facts and figures 2018. Atlanta; American Cancer Society; 2018
18	Cho H, Nishiike S, Yamamoto Y, Takenaka Y, Nakahara S, Yasui T, Hanamoto A and Inohara H: Docetaxel, Cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx. 42:396–400. 2015. View Article : Google Scholar : PubMed/NCBI
19	Lorch J, Goloubeva O, Haddad R, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J and Sammartino DE: Induction chemotherapy with Cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomized phase 3 trial. Lancet Oncol. 12:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
20	Porceddu SV, Scotté F, Aapro M, Salmio S, Castro A, Launay-Vacher V and Licitra L: treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin-based therapy. Front Oncol. 9:15222020. View Article : Google Scholar : PubMed/NCBI
21	Szturz P, Cristina V, Herrera Gómez RG, Bourhis J, Simon C and Vermorken JB: Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: Recommendations for clinical practice. Front Oncol. 9:4642019. View Article : Google Scholar : PubMed/NCBI
22	Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, Zhang F, Liu LZ, Tian L, Lin AH, et al: The cumulative cisplatin dose affects the long-term survival outcomes of patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Sci Rep. 6:243322016. View Article : Google Scholar : PubMed/NCBI
23	Le X and Hanna EY: Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. Ann Transl Med. 6:2292018. View Article : Google Scholar : PubMed/NCBI
24	Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, et al: Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck. 38(Suppl 1): E2151–E2158. 2016. View Article : Google Scholar
25	Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Adelstein D, Van Gestel D and Vermorken JB: Low-dose vs. High-dose cisplatin: Lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol. 9:862019. View Article : Google Scholar : PubMed/NCBI
26	Mashhour K and Hashem W: Cisplatin weekly versus every 3 weeks concurrently with radiotherapy in the treatment of locally advanced head and neck squamous cell carcinomas: What is the best dosing and schedule? Asian Pac J Cancer Prev. 21:799–807. 2020. View Article : Google Scholar : PubMed/NCBI
27	Nouman M, Haider G, Bukhari N, Yousuf A, Nouman R, Shaikh MR, Hussain S, Pavan B, Rahool R, Memon P, et al: Response rate of cisplatin plus docetaxel as primary treatment in locally advanced head and neck carcinoma (squamous cell types). Asian Pac J Cancer Prev. 21:825–830. 2020. View Article : Google Scholar : PubMed/NCBI
28	Duan X, He C, Kron SJ and Lin W: Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 8:776–791. 2016. View Article : Google Scholar : PubMed/NCBI
29	Kayyali MN, Ramsey AJ, Higbee-Dempsey EM, Yan L, O'Malley BW Jr, Tsourkas A and Li D: The development of a nano-based approach to alleviate cisplatin-induced ototoxicity. J Assoc Res Otolaryngol. 19:123–132. 2018. View Article : Google Scholar : PubMed/NCBI
30	Mehtala JG, Torregrosa-Allen S, Elzey BD, Jeon M, Kim C and Wei A: Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. Nanomedicine (Lond). 9:1939–1955. 2014. View Article : Google Scholar
31	Miao L, Guo S, Zhang J, Kim WY and Huang L: Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv Funct Mater. 24:6601–6611. 2014. View Article : Google Scholar : PubMed/NCBI
32	Miao L, Wang Y, Lin CM, Xiong Y, Chen N, Zhang L, Kim WY and Huang L: Nanoparticle modulation of the tumor microen-vironment enhances therapeutic efficacy of cisplatin. J Control Release. 217:27–41. 2015. View Article : Google Scholar : PubMed/NCBI
33	Green HN, Martyshkin DV, Rosenthal EL and Mirov SB: A minimally invasive multifunctional nanoscale system for selective targeting, imaging, and NIR photothermal therapy of malignant tumors. In: Proceedings of the Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III; 7910. SPIE BiOS; San Francisco, CA. 2011
34	Green HN, Crockett SD, Martyshkin DV, Singh KP, Grizzle WE, Rosenthal EL and Mirov SB: A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression. Int J Nanomedicine. 9:5093–5102. 2014. View Article : Google Scholar : PubMed/NCBI
35	Sebaugh JL: Guidelines for accurate EC50/IC50 estimation. Pharm Stat. 10:128–134. 2011. View Article : Google Scholar
36	Guo S, Lin CM, Xu Z, Miao L, Wang Y and Huang L: Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano. 8:4996–5009. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zhou F, Feng B, Yu H, Wang D, Wang T, Liu J, Meng Q, Wang S, Zhang P, Zhang Z and Li Y: Cisplatin prodrug-conjugated gold nanocluster for fluorescence imaging and targeted therapy of the breast cancer. Theranostics. 6:679–687. 2016. View Article : Google Scholar : PubMed/NCBI
38	Hackenberg S, Scherzed A, Harnisch W, Froelich K, Ginzkey C, Koehler C, Hagen R and Kleinsasser N: Antitumor activity of photo-stimulated zinc oxide nanoparticles combined with paclitaxel or cisplatin in HNSCC cell lines. J Photochem Photobiol B. 114:87–93. 2012. View Article : Google Scholar : PubMed/NCBI
39	Hackenberg S, Scherzed A, Kessler M, Froelich K, Ginzkey C, Koehler C, Burghartz M, Hagen R and Kleinsasser N: Zinc oxide nanoparticles induce photocatalytic cell death in human head and neck squamous cell carcinoma cell lines in vitro. Int J Oncol. 37:1583–1590. 2010.PubMed/NCBI